Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200704Resistin and prooxidant-antioxidant balance: Markers to discriminate acute coronary syndrome from stable angina46541072210.22122/arya.v16i2.1944ENAli PourmoghaddasInterventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-5684-0426Armin ElahifarIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-5667-3077Faramarz DarabiHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranAhmad MovahedianDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences AND Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, IranAfshin AmirpourAssistant Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranNizal Sarrafzadegan2- Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
6- Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, Canada0000-0002-8352-0540Journal Article20181228BACKGROUND: Resistin and oxidative stress may play a role in the pathogenesis of coronary heart disease (CHD) including acute coronary syndrome (ACS). The aim of this study was to investigate the role of serum resistin and prooxidant-antioxidant balance (PAB) in ACS occurrence in order to differentiate it from stable angina. Moreover, we aimed to determine the correlation between resistin and PAB in patients with ACS and its difference from patients with stable CHD.METHODS: This cross-sectional, descriptive study was conducted on 50 patients with ACS and 50 patients with stable CHD who underwent coronary angiography (CAG). Serum resistin level was measured using enzyme-linked immunosorbent assay (ELISA). PAB and other variables were analyzed using standard methods.RESULTS: A significant increase in serum resistin and PAB was observed in patients with ACS (2.55 ± 0.13 ng/ml and 123.5 ± 5.58 HK unit, respectively) compared to patients with stable CHD (1.53 ± 0.12 ng/ml and 95.9 ± 2.7 HK unit, respectively) (P < 0.001). In addition, a significant positive correlation was seen between serum resistin and PAB in patients with ACS (r = 0.39; P = 0.005), but this correlation was not found in patients with stable CHD (r = 0.21; P = 0.140). Resistin (r = 0.52; P < 0.001) and PAB (r = 0.55; P < 0.001) were significantly associated with high-sensitivity C-reactive protein (hs-CRP) in patients with ACS, but this association was not found in patients with stable CHD (resistin: r = 0.24; P = 0.090; PAB: r = -0.02: P = 0.910).CONCLUSION: High serum resistin or PAB levels, and their association with the occurrence of ACS, can be used as a robust discriminating factor to differentiate ACS from stable CHD. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200514The psychometric properties of the Hypertensive Treatment Adherence Scale55711072310.22122/arya.v16i2.1543ENMahlagha DehghanAssistant Professor, Nursing Research Center, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran0000-0002-4205-829XNahid Dehghan-NayeriProfessor, Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran0000-0003-1594-6790Sedigheh IranmaneshAssociate Professor, Nursing Research Center, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, IranJournal Article20161207BACKGROUND: Hypertension (HTN) is a public concern and treatment adherence has a key role in its management. This study was conducted to develop and test the reliability and validity of the Hypertensive Treatment Adherence scale (HTA-scale).METHODS: This was a cross-sectional and methodological study. After item generation using a qualitative study and literature review, the scale was developed. The psychometric properties of the scale were evaluated using face, content, construct, and criterion validity and reliability.RESULTS: Data analysis showed that the HTA-scale had acceptable face and content validity. The scale had excellent stability [Intraclass correlation coefficient (ICC) = 0.74] and good acceptability and internal consistency (Cronbach's a = 0.76). Exploratory factor analysis (EFA) showed that the HTA-scale consisted of 6 meaningful subscales including medication adherence and monitoring, adherence to safe diets, avoiding unsafe diets, self-medication, activity, and smoking. Participants in the controlled blood pressure group had significantly higher HTA-scale scores than the uncontrolled blood pressure group. At the cut-off point of 86, the scale had significant sensitivity and specificity.CONCLUSION: All of the psychometric properties of the HTA-scale achieved the standard level and were sufficient to recommend this scale for patients with HTN. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200514Knowledge production in Iranian cardiovascular research centers: A way to reduce the burden of disease72781072410.22122/arya.v16i2.2022ENAsghar EbadifarDeputy for Research and Technology, Ministry of Health and Medical Education AND Dentofacial Deformities Research Center, Research Institute of Dental Sciences AND Department of Orthodontics, School of Dental, Shahid Beheshti University of Medical Sciences Tehran, IranMonir Barabaran-EftekhariDeputy for Research and Technology, Ministry of Health and Medical Education, Tehran, Iran0000-0002-8896-9726Katayoun FalahatDeputy for Research and Technology, Ministry of Health and Medical Education, Tehran, IranMasoumeh EltemasiDeputy for Research and Technology, Ministry of Health and Medical Education, Tehran, IranZahra SobhaniDeputy for Research and Technology, Ministry of Health and Medical Education, Tehran, IranElham GhalenoeiDeputy for Research and Technology, Ministry of Health and Medical Education, Tehran, IranElham HabibiDeputy for Research and Technology, Ministry of Health and Medical Education, Tehran, IranNizal SarrafzadeganIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranShahin AkhondzadehiDeputy for Research and Technology, Ministry of Health and Medical Education AND Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IranReza MalekzadehDeputy for Research and Technology, Ministry of Health and Medical Education AND Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, IranJournal Article20190601BACKGROUND: According to the World Health Organization (WHO), non-communicable diseases (NCDs) including cardiovascular diseases (CVDs) will be responsible for almost 70% of all deaths in 2020. Therefore, knowledge production to find suitable ways to prevent, diagnosis, and effectively cover this disease in research centers is mandatory. Therefore, the present study is carried out with the aim to examine the results of studies performed in three years in Iranian cardiovascular centers.METHODS: Iranian cardiovascular research centers with more than three years of activity from 2015 to 2017 were evaluated. Research output, international collaboration, high quality publication, total citation, and average h-index (H) were evaluated and scored.RESULTS: 23 cardiovascular diseases research centers (CVDRCs) related to 15 universities of Medical Sciences (UMSs) were evaluated. The mean and standard deviation (SD) of age of the research activities in CVDRCs was 11.47 ± 8.60 years. Based on the research ranking, the first three centers were Isfahan Cardiovascular Research Center, Iran, Tehran Heart Center, and Shaheed Rajaei Cardiovascular Medical and Research Center, Iran, respectively, all of which have independent budget line. However, there is not any CVD research center in some provinces such as Zanjan, Kurdistan, Lorestan, and Arak, Iran.CONCLUSION: Mission oriented research activities in Iranian cardiovascular research centers may be effective in reducing the burden of CVDs. Moreover, establishment of CVD research centers in high risk areas may be useful.Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200514Accuracy of the amount of trans-fatty acids in traffic light labelling of traditional sweets distributed in Isfahan, Iran79841072510.22122/arya.v16i2.2005ENNeda GhazaviPhD Candidate, Department of Food Hygiene, College of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran0000-0003-0287-7044Ebrahim RahimiProfessor, Department of Food Hygiene, College of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, IranZahra EsfandiariAssistant Professor, Food Security Research Center AND Department of Food Science and Technology, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran0000-0003-2399-2762Amir ShakerianAssociate Professor, Department of Food Hygiene, College of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, IranJournal Article20190426BACKGROUND: High consumption of trans-fatty acids (TFAs) is introduced as dietary risk factor of cardiovascular diseases (CVDs). The accuracy of the information shown on the traffic light (TL) labelling has a significant influence on consumers to reduce TFA content in foods. This study is conducted aiming to determine the TFA content in traditional sweets distributed in Isfahan, Iran. Furthermore, the accuracy of the amount of TFAs on TL was considered by comparing it with the experimentally analyzed values.METHODS: In this cross-sectional study, a total of 99 Iranian traditional sweets with a TL label were randomly collected from confectionary shops located in Isfahan. TFAs were analyzed by gas chromatography (GC).RESULTS: TFAs were detected in all samples with the total average of 1.6 ± 0.3% in total fat (range of 0.040 ± 0.001 to 7.900 ± 1.100%). More than half of the samples had less than 2% of TFAs in the total fat. Overall, 81.8% of the studied products with TL labelling showed a discrepancy in the TFAs in the values analyzed in laboratory.CONCLUSION: In the present study, the discrepancy of TFAs in the experimentally measured values with TL food labelling was observed in more than 80% of Iranian traditional sweets. Most of the samples contained less than 2% of TFAs that is defined as a limit in Iran Food and Drug Administration (IFDA). These findings could be alarming for the consumers of this kind of products. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200527Comparison of survival rate and complications of percutaneous coronary intervention, coronary artery bypass graft, and medical treatment in patients with left main and/or three vessel diseases85931072610.22122/arya.v16i2.2019ENAlireza KhosraviProfessor, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000.0003.0736.2090Mehrbod VakhshooriHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranVahid SharifHypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranFarshad Roghani-DehkordiProfessor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-8529-7522Jamshid NajafianAssociate Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-1472-1218Asieh MansouriAssistant Professor, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-8507-6738Journal Article20190524BACKGROUND: The probable complications of 3 different cardiovascular diseases treatment options including percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and medical therapy (MT), especially in individuals suffering from left main (LM) and/or three vessel diseases (3VDs), have received less attention. Thus, the aim of this study was to compare the complications of the aforementioned therapeutic strategies in patients admitted with LM coronary artery disease (CAD) and/or having 3VDs.METHODS: From March 2018 to March 2019, a total number of 251 eligible individuals (87, 86, and 78 subjects treated with PCI, CABG, and MT, respectively) were recruited in this cohort study. After the initiation of treatment, all individuals were followed for 6 months. Occurrence of any complications including chest pain (CP), re-hospitalization due to cardiac problems, heart failure (HF), death, myocardial infarction (MI), and stroke as well as major adverse cardiac events (MACE) were assessed.RESULTS: Significantly lower percentages of CP, readmission, and HF were observed in the CABG group compared to the PCI and MT groups (24.4% vs. 47.1% and 53.9%, P < 0.001; 3.5% vs. 13.8% and 5.1%, P = 0.020; 1.2% vs. 2.3% and 9%; P = 0.040, respectively). Further analysis revealed an increased likelihood of hospitalization in the PCI group (OR: 3.82, 95% CI: 1.01-14.41, P = 0.040), and a lower risk of CP and HF occurrence in the CABG group subjects compared to the MT group (OR: 0.28, 95% CI: 0.13-0.62, P = 0.002 and OR: 0.05, 95% CI: 0.004-0.71, P = 0.030, respectively). This pattern was also observed in the PCI group in terms of HF (OR: 0.12, 95% CI: 0.02-0.83, P = 0.030).CONCLUSION: Patients suffering from LM and/or 3VDs would most likely benefit from CABG followed by PCI, rather than MT. Further large-scale studies are required to confirm these results.Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200704Enzymatic antioxidant system and endothelial function in patients with metabolic syndrome941011072710.22122/arya.v16i2.1813ENFariba SakhaeiIsfahan Pharmaceutical Sciences Research Center AND Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran0000-0003-2589-0284Mahtab KeshvariIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranSedigheh AsgaryProfessor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-7724-4802Leila SalehizadehProfessor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranAli RastqarDepartment of Psychiatry and Neuroscience, Laval University, Quebec, QC, CanadaSeyyed Ziaedin Samsam-ShariatAssociate Professor, Isfahan Pharmaceutical Sciences Research Center AND Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-6328-9505Journal Article20180703BACKGROUND: This study examined the relationship between serum glutathione peroxidase 1 (GPx-1) activity and endothelial dysfunction in the subjects with and without metabolic syndrome (MetS).METHODS: This case-control study was conducted on 76 subjects, 38 were patients with MetS and 38 were without MetS. The demographic, clinical, and laboratory features of the subjects were measured and then compared. The MetS was diagnosed according to the definitions of the National Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF). Serum GPx-1 activity was measured by standard methods. Endothelial dysfunction was assessed with flow-mediated dilation (FMD) technique.RESULTS: In case-control study of 76 subjects, all of MetS risk factors including abdominal obesity, triglyceride (TG), low serum level of high-density lipoprotein cholesterol (HDL-C), hypertension (HTN), and fasting plasma glucose (FPG) were significantly higher than healthy individuals (P < 0.050). FMD was significantly lower than normal subjects (P < 0.050). Serum GP-1 activity was significantly lower in patients with MetS compared to normal subjects (21.7 ± 13.5 vs. 79.0 ± 38.6, respectively) (P = 0.001). The value of GPx-1 was significantly correlated with diastolic blood pressure (DBP) (r = -0.249, P = 0.040), C-reactive protein (CRP) (r = -0.409, P = 0.014), and FMD (r = 0.293, P = 0.050) in patients with MetS. The results of logistic regression showed that a unite increase in CRP (mg/dl), FMD (%), and endothelin-1 (ET-1) (pg/ml) and a unit decrease in GPx significantly increased the odds ratio (OR) of MetS; after adjusting for age and sex the results remained significant except for FMD (P < 0.050)CONCLUSION: Endothelial dysfunction is related to serum GPx-1 activity in patients with MetS. GPX-1 activity is associated with risk of cardiovascular diseases (CVDs) and peripheral vascular diseases (PVDs) in patients with MetS.Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200514Large pericardial mesothelial cyst coexisting with hypertrophic obstructive cardiomyopathy1021041072110.22122/arya.v16i2.2014ENAnita SadeghpourProfessor, Department of Cardiology, Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran0000-0002-8485-0058Alireza Alizadeh-GhavidelAssociate Professor, Department of Cardiac Surgery, Heart Valve Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IranKambiz MozaffariAssistant Professor, Department of Pathology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IranHamidreza PouraliakbarAssociate Professor, Department of Radiology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IranBehshid GhadrdoostAssistant Professor, Department of Physiology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IranMohaddeseh BehjatiFellowship, Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran0000-0002-6533-5085Journal Article20190514BACKGROUND: Pericardial mesothelioma cyst occurs rarely, and is often found incidentally. The coexistence between large pericardial mesothelial cyst and hypertrophic obstructive cardiomyopathy (HOCM) can make difficulties in medical management.CASE REPORT: Our case was a 33-year-old man presented with dizziness and pallor while standing since four years before, and recent syncope. On admission, transthoracic echocardiography reveled presence of hypertrophic cardiomyopathy in association with relatively small right ventricular and atrium due to compression effect by a large echo-free space at the right side of heart suggestive of pericardial cyst. Cardiac computed tomography confirmed presence of HOCM and large pericardial cyst. Patient underwent surgical septal myectomy and large mesothelial pericardial cyst excision because of persistent symptoms and compression effect of cyst on the right chambers despite beta-blocker therapy.CONCLUSION: To best of our knowledge, the coexistence of the large pericardial mesothelial cyst and HOCM has not been reported before. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395516220200301Journal Index1072010.22122/arya.v16i2.2281ENIndex Journal0000-0002-1825-0097Journal Article20201024Click to download the index of this issue